• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Integra LifeSciences Holdings (IART), Why Is It Getting Attention Now?

    Simply Wall St·08/22/2026 12:28:43
    Listen to the news

    Recent share performance and business snapshot

    Integra LifeSciences Holdings (IART) has drawn fresh attention after a mixed stretch for the stock, with a gain over the past 3 months but a decline over the past month and past week.

    The company has a market value of about US$1.29b and last closed at US$16.74 on 19 August 2026. Reported annual revenue is US$1.65b, with a net loss of US$7.24m, and a neutral value score of 5.

    Integra LifeSciences Holdings generates most of its revenue from Specialty Surgery at US$1.21b, with Tissue Reconstruction contributing about US$439m. The United States is the largest geographic market at roughly US$1.21b of revenue, followed by Asia Pacific and Europe.

    See our latest analysis for Integra LifeSciences Holdings.

    Looking across time frames, Integra LifeSciences Holdings has a 30 day share price return of down 11.05%, a 90 day share price return of 10.86%, and a year to date share price return of 39.38%. The 1 year total shareholder return is 12.65% and the 5 year total shareholder return shows a decline of 77.08%, which points to improving near term momentum after a difficult longer term period.

    If Integra LifeSciences Holdings has you reassessing where growth might come from next, it can be useful to widen your search using our screener for 41 healthcare AI stocks

    Integra LifeSciences Holdings has bounced in the short term yet remains well below its 5 year mark, which leaves a key issue hanging. Do recent gains mirror improving fundamentals, or is sentiment simply resetting the valuation?

    Most Popular Narrative: 38% Undervalued

    The most followed narrative for Integra LifeSciences Holdings pegs fair value at $27, well above the last close at $16.74. That gap comes from a detailed set of assumptions about margins, growth, and payout for patience.

    Analysts broadly agree that Integra's Compliance Master Plan and supply chain upgrades will stabilize operations and restore revenue; however, this may actually drive a structural step change in cost efficiency and supply reliability, leading to gross margin and earnings expansion well beyond conservative estimates as operational bottlenecks are permanently resolved across legacy and newly acquired sites.

    Read the complete narrative.

    Want to see what sits behind that confidence in Integra LifeSciences Holdings? The narrative leans on a shift from losses to steady profitability, paired with a future earnings multiple that assumes the market rewards that turnaround.

    Result: Fair Value of $27 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, you also need to weigh ongoing quality and regulatory issues, along with slower than hoped customer recovery after recalls, which could quickly undermine this Integra LifeSciences Holdings narrative.

    Find out about the key risks to this Integra LifeSciences Holdings narrative.

    Next Steps

    With sentiment on Integra LifeSciences Holdings split between concern over risks and optimism about rewards, it helps to see the numbers firsthand and act while the picture is fresh. To weigh both sides in context, start with the 3 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond Integra LifeSciences Holdings?

    If Integra LifeSciences Holdings has sharpened your focus on quality and risk, now is the time to broaden your watchlist with fresh, data backed stock ideas.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.